Overview
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 | |
| Contingent liabilities | $1,569,244 |
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 81 days for 2021).
- 2025filed
- 202431/07/2025
- 202304/07/2024
- 202216/07/2023
- 202104/10/2022
- 202030/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
The following is authorized to submit declarations of will on behalf of the company: 1. in the case of a one-person management board, the sole member of the management board acting independently; 2. in the case of a multi-member management board, if no member of the management board for financial matters (CFO) is appointed, two members of the management board jointly; 3. in the case of a multi-member management board, if a member of the management board for financial matters (CFO) is appointed, the member of the management board for financial matters jointly with another member of the management board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 368 | $9,940.57 | 14.3191% | |
Łukasz Lebiedziński age 50 | 1,101 | $27,309.56 | 39.3385% |
Jakub Paweł Szczerbuk age 43 | 1,101 | $27,309.56 | 39.3385% |
Others | 194 | $4,862.24 | 7.0039% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-04-01.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
5 public aid cases recorded, with a total value of $1,463,891.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 6, 2024 | Aid for research and development projects: experimental development | $668.6K$668,588 | Prezes Agencji Badań Medycznych | |
| Dec 6, 2024 | Aid for research and development projects: industrial research | $335.7K$335,655 | Prezes Agencji Badań Medycznych | |
| Mar 3, 2023 | Aid for SME access to finance — aid for start-ups | $199.9K$199,900 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Therapiq sp. z o.o. | $7,482.34 | therapiq.eu | ||
| NEO Ortho Pracownia Sztuki Ortopedycznej sp. z o.o. | $5,662.74 | neoortho.pl | ||
| PD Meds sp. z o.o. | $3,515.83 | pdmeds.com | ||
| Bioimplanti sp. z o.o. | $1,660.39 | bioimplanti.pl | ||
| Royal Method sp. z o.o. | $1,089.26 | royal-method.com | ||
| Hetalox sp. z o.o. | $965.71 | hetalox.com | ||
| Telemedical Innovations S.A. | $872.98 | telemedicalinnovations.com | ||
| Dentioscan sp. z o.o. | $118.24 | dentioscan.pl | ||
| Mindhand sp. z o.o. | $0.78 | mindhand.pl | ||
| Bodyscope sp. z o.o. | $0.05 | bodyscope.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-07-31 | Share capital increase (256,700.00 PLN → 257,000.00 PLN) | |
| 2025-07-31 | Name change (Tjle → Britescope) | |
| 2023-04-21 | Share capital increase (220,000.00 PLN → 256,700.00 PLN) | |
| 2023-01-13 | Share capital increase (6,000.00 PLN → 220,000.00 PLN) | |
| 2020-03-11 | Address change (Ul. Dworcowa 41a/2, 10-437, Olsztyn → Ul. Franciszka Barcza 58/U18, 10-685, Olsztyn) |
FAQ
Last updated: 2026-04-12
